Extended Data Table 6 Thyroid hormones at baseline and change from baselinea at Week 52 (observed data)

From: Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

  1. aFree thyroxine (FT4) reported as both change from baseline (CFB) and percent change from baseline (%CFB) at Week 52. All other thyroid hormones reported as change from baseline (CFB) at Week 52. This trial was designed to maintain an overall study-wise type I error rate of α = 0.05 for the key secondary endpoints only. The error rate was controlled by first splitting the overall two-sided α = 0.05 into 2 partitions via the Bonferroni method, and then the key secondary endpoints tested in a prespecified hierarchical order. An ANCOVA model was used whereby the baseline value of the dependent variable was included as covariate instead of LDL-C CFB, change from baseline; CI, confidence interval; DB, double-blind; LSM, least squares mean; OL, open-label; RT3, reverse triiodothyronine; SE, standard error; FT3, free triiodothyronine; FT4, free thyroxine; TSH, thyroid-stimulating hormone.
Back to article page